Baldwin Wealth Partners LLC MA Acquires 11,609 Shares of Novo Nordisk A/S $NVO

by · The Cerbat Gem

Baldwin Wealth Partners LLC MA grew its holdings in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 6.8% in the second quarter, HoldingsChannel.com reports. The fund owned 181,125 shares of the company’s stock after purchasing an additional 11,609 shares during the period. Baldwin Wealth Partners LLC MA’s holdings in Novo Nordisk A/S were worth $12,501,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Copeland Capital Management LLC lifted its position in Novo Nordisk A/S by 184.8% in the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company’s stock worth $27,000 after buying an additional 255 shares during the last quarter. North Capital Inc. bought a new stake in Novo Nordisk A/S in the 1st quarter worth approximately $27,000. Stone House Investment Management LLC bought a new stake in Novo Nordisk A/S in the 1st quarter worth approximately $30,000. Disciplina Capital Management LLC lifted its position in Novo Nordisk A/S by 162.3% in the 1st quarter. Disciplina Capital Management LLC now owns 480 shares of the company’s stock worth $33,000 after buying an additional 297 shares during the last quarter. Finally, Spirit of America Management Corp NY bought a new stake in Novo Nordisk A/S in the 1st quarter worth approximately $35,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

Shares of Novo Nordisk A/S stock opened at $58.64 on Friday. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.56. The business’s 50 day simple moving average is $55.26 and its two-hundred day simple moving average is $63.33. The stock has a market capitalization of $261.83 billion, a P/E ratio of 16.11, a price-to-earnings-growth ratio of 2.70 and a beta of 0.68. Novo Nordisk A/S has a one year low of $45.05 and a one year high of $120.56.

Novo Nordisk A/S (NYSE:NVO – Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.93 by $0.04. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%.The firm had revenue of $11.69 billion for the quarter, compared to analysts’ expectations of $77.51 billion. Analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The firm also recently announced a semi-annual dividend, which was paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th were paid a dividend of $0.4119 per share. The ex-dividend date of this dividend was Monday, August 18th. This represents a dividend yield of 240.0%. Novo Nordisk A/S’s payout ratio is 22.53%.

Analyst Upgrades and Downgrades

NVO has been the subject of a number of recent research reports. Weiss Ratings restated a “hold (c-)” rating on shares of Novo Nordisk A/S in a research report on Saturday, September 27th. Berenberg Bank upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Wednesday, September 17th. Morgan Stanley downgraded Novo Nordisk A/S from an “overweight” rating to an “underweight” rating and dropped their target price for the stock from $59.00 to $47.00 in a research report on Monday, September 29th. BNP Paribas raised Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a research note on Wednesday, August 13th. Finally, Dbs Bank raised Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, August 22nd. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $77.50.

Check Out Our Latest Analysis on Novo Nordisk A/S

About Novo Nordisk A/S

(Free Report)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

See Also

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO – Free Report).